Table 1.
Comparison of demographic, clinical, and CSF characteristics between critically ill and non-critically ill patients.
| Critically Ill subgroup | Non-critically Ill subgroup | P-value | |
|---|---|---|---|
| DEMOGRAPHIC | |||
| Gender(female) | 8/14 | 7/12 | 1 |
| Age | 20(15,26) | 20.5(17,31) | 0.502 |
| CLINICAL INFORMATION | |||
| Fever | 13/14 | 4/12 | 0.003* |
| Headache | 10/14 | 4/12 | 0.113 |
| Psychiatric behaviour | 12/14 | 11/12 | 1 |
| Cognition dysfunction | 4/14 | 6/12 | 0.422 |
| Memory impairment | 4/14 | 9/12 | 0.047* |
| Speech dysfunction | 4/14 | 8/12 | 0.113 |
| Seizures | 13/14 | 11/12 | 1 |
| Movement disorder | 9/14 | 6/12 | 0.692 |
| Central hypoventilation | 7/14 | 0/12 | 0.006* |
| Autonomic dysfunction | 10/14 | 5/12 | 0.233 |
| Decreased consciousness | 11/14 | 3/12 | 0.016* |
| Glasgow Coma Scale | 5(3,6) | 11.5(7,15) | 0.005* |
| Days till diagnosis | 20(15,25) | 17.5(13.5,34.5) | 0.959 |
| Days in hospital | 61(54,120) | 16.5(13,27.5) | 0.0002* |
| Mechanical ventilation | 10/14 | 0/12 | 0.0001* |
| Tumor | 7/14 | 1/12 | 0.036* |
| Tumor in female | 7/8 | 1/7 | 0.01* |
| Elevated CSF protein | 2/14 | 5/12 | 0.19 |
| CSF leukocyte | 0.728 | ||
| ~5 | 8/14 | 6/12 | |
| 6~50 | 5/14 | 5/12 | |
| 51~ | 1/14 | 1/12 | |
| Oligoclonal band | 0.642 | ||
| Negative | 6/13 | 3/10 | |
| Suspected | 0/13 | 5/10 | |
| Positive | 7/13 | 2/10 | |
| Antibody titers in CSF | 0.324 | ||
| ~1:10 | 1/14 | 1/12 | |
| 1:32 | 3/14 | 5/12 | |
| 1:100~ | 10/14 | 6/12 | |
| Antibody titers in serum | 0.040* | ||
| Negative | 3/14 | 7/12 | |
| 1:10 | 2/14 | 1/12 | |
| 1:32~ | 9/14 | 4/12 | |
| SECOND-LINE IMMUNOTHERAPY | |||
| MMF | 9/14 | 4/12 | 0.238 |
| MTX | 4/14 | 0/12 | 0.100 |
| CTX | 1/14 | 0/12 | 1 |
| RTX | 1/14 | 1/12 | 1 |
| No 2nd-line Immunotherapy | 4/14 | 8/12 | 0.113 |
*
p < 0.05.
CSF, cerebrospinal fluid; MMF, mycophenolate mofetil; MTX, methotrexate; CTX, cyclophosphamide; RTX, rituximab.